Lewis Blood Group Percentage Distribution among Indigenes of Ogoni Ethnicity in Rivers State, Nigeria

Aim: We attempted to determine the frequency and percentage distribution of Lewis blood group antigens among indigenes of Ogoni ethnicity in Rivers State, Nigeria. Study Design: The study consisted of 101 Ogoni people, who were apparently healthy and free from transfusion transmissible infections confirmed by serological screening. Ogoniland is located along the Niger Delta Eastern edge, and to the north-east of the Imo River and Port Harcourt city. All subjects were recruited and their blood samples were collected. The presence of Lewis-a and -b (Lea/Leb) blood group was examined using Anti-Lea and Leb monoclonal antibody, respectively (Lorne Laboratories). Results: Lea and Leb blood group was observed in 17.8% and 11.9%, respectively. Conclusion: Lea and Leb in this population was observed less frequently than those in other population previously reported. The Lewis antigen was reported to be associated with thrombotic disorders and Helicobacter pylori infection. Further studies may be directed to examine the association between Lewis blood group antigens and the risk of these conditions in Ogoni subjects.

Computational analysis of carbohydrate recognition based on hybrid QM/MM modeling: a case study of norovirus capsid protein in complex with Lewis antigen

Computational modeling of carbohydrate recognition in norovirus capsid protein.

The prevalence of secretor status and co-expression of lewis antigen in voluntary blood donors

Background: Blood group substances are present in soluble form in a majority of individuals in secretion such as saliva and body fl uids. Secretor status refers to the presence (SeSe and Sese) or absence (sese) of secretor gene which secrete ABH soluble substances. Secretor status can be used to resolve ABO discrepancies of people whose blood group cannot be identified by routine blood grouping and it can also help in identifying patients who may be a high risk group for getting certain diseases. Aims and Objectives:Our aim and objectives of the study is to fi nd out the Prevalence of Secretor Status and Co-expression of Lewis Antigens among the Voluntary Blood Donors.Materials and Methods:This study was conducted in sixty volunteers and the method used to determine the secretor status was hemagglutination inhibition method. Their blood was used to detect the type of Lewis (Le) antigen since the type of Lewis antigen correlated with the secretor status of the individual.Results:Among the sixty subjects tested, forty fi ve of them were found to be secretors and fifteen of them were Non-secretors. The number of Lewis (a+b-) individuals were twelve, Lewis (a-b+) were thirty nine and Lewis (a-b-) were nine.Conclusion:The prevalence of secretors was 75% and non-secretors were 25% respectively. We found 65 % of the volunteers were found to be Le (a-b+) positive, 20% were Le (a+b-) and the remaining 15% were Le (a-b-) which correlated with the ABH antigen secretor status.Asian Journal of Medical Sciences Vol.7(5) 2016 93-96

CA19-9 and surgical margin status (SMS) associations with local-regional (LRF) and distant failure (DF) in patients (Pts) with pancreatic cancer: RTOG 9704 secondary analysis.

347 Background: 9,704 was the first phase 3 pancreatic cancer trial to validate the prognostic value of postresection CA19-9 for overall survival (OS), with values > 90/180 associated with worse OS. All pts received adjuvant gemcitabine or 5-FU and chemo-radiotherapy (RT). This analysis evaluates patterns of disease failure. Methods: SMS was negative, positive, or unknown. CA19-9 was analyzed at cut points 90, 180 and continuously. LRF and DF were estimated by cumulative incidence and Gray’s test compared. Cox hazard models were used for multivariate analyses (MVA) and included treatment, tumor site, size and nodal status. To adjust for multiple comparisons a p-value < 0.01 is statistically significant and 0.01 to < 0.05 a trend. Results: 538 pts accrued, with 451 eligible and analyzable for SMS and 385 for CA19-9. For CA19-9, 132 (34%) were Lewis Antigen negative (no CA19-9 expression), 200 (52%) < 90 and 220 (57%) < 180. 188 (42%) had negative margins, 152 (34%) positive and 111 (25%) unknown (i.e., no margin comment in path report; shown to have outcomes similar to negative margin pts). Pts with CA19-9 ≥ 180 were more likely to have tumors ≥ 3 cm and pts with positive SMS more likely to have KPS 60 - 80, T3/T4, or N1 disease. On univariate analysis (UVA) CA19-9 cut at 90 was associated with significant increases in both LRF (trend) and DF; in the gemcitabine arm this was seen in DF, not in LRF; in the 5-FU arm it was seen in both. Results were similar at the 180 cut point and continuously. SMS on UVA was not associated with increase in LRF/DF; see Table. On MVA, CA19-9 > 90 was significantly associated with LRF and DF; positive SMS showed only a trend for DF. Conclusions: Postresection CA19-9 has significant association with both LRF and DF not seen with SMS. These findings support continued use of RT in trials and consideration of dose intensification among pts with elevated postresection CA19-9. Grants: NCI U10, CA21661, CA37422, CA180868, CA180822. Clinical trial information: 0000000. [Table: see text]